Sarcomas

Pediatr Clin North Am. 2015 Feb;62(1):179-200. doi: 10.1016/j.pcl.2014.09.012.

Abstract

Malignant bone tumors (osteosarcoma, Ewing sarcoma) and soft-tissue sarcomas (rhabdomyosarcoma, nonrhabdomyosarcoma) account for approximately 14% of childhood malignancies. Successful treatment of patients with sarcoma depends on a multidisciplinary approach to therapy, including oncology, surgery, radiation oncology, radiology, pathology, and physiatry. By combining systemic treatment with chemotherapy and primary tumor control using surgery and/or radiation, survival rates for localized disease range from 70% to 75%. However, children with metastatic or recurrent disease continue to have dismal outcomes. A better understanding of the biology underlying both bone and soft-tissue sarcomas is required to further improve outcomes for children with these tumors.

Keywords: Bone; Ewing’s; Nonrhabdomyosarcoma; Osteosarcoma; Rhabdomyosarcoma; Soft-tissue sarcoma.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms / pathology*
  • Bone Neoplasms / therapy
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Humans
  • Sarcoma / pathology*
  • Sarcoma / therapy